Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Carboprost Tromethamine Market to Reach USD 2.79 Billion by 2031 as Postpartum Hemorrhage Treatment Demand Rises

globenewswire.com
PFE Pfizer Inc. is listed as a key company in the carboprost tromethamine market. The article does not provide specific sentiment towards Pfizer's performance or its role in this particular market, thus the sentiment is neutral. RDY Dr. Reddy's Laboratories Ltd is mentioned as a key player. The article does not offer specific positive or negative commentary on the company's involvement or performance in the carboprost tromethamine market, resulting in a neutral sentiment. TEVA Teva Pharmaceutical Industries is identified as a significant company in the market. The article does not contain explicit positive or negative statements about Teva's specific contributions or market position, leading to a neutral sentiment. AMRX Amneal Pharmaceuticals LLC is listed among the key companies. The article does not provide details on Amneal's specific performance or outlook within the carboprost tromethamine market, hence the sentiment is neutral. SUN Sun Pharma is mentioned as a key company. The article does not offer specific positive or negative insights into Sun Pharma's operations or market share related to carboprost tromethamine, resulting in a neutral sentiment. GLAD Gland Pharma is identified as a key player. The article does not contain specific positive or negative statements about Gland Pharma's contributions or market standing in the carboprost tromethamine sector, leading to a neutral sentiment.

Carboprost Tromethamine Market to Reach USD 2.79 Billion by 2031 as Postpartum Hemorrhage Treatment Demand Rises Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Carboprost Tromethamine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Carboprost Tromethamine Market to Reach USD 2.79 Billion by 2031 as Postpartum Hemorrhage Treatment Demand Rises

The global carboprost tromethamine market was valued at USD 1.99 billion in 2025 and is projected to increase from USD 2.11 billion in 2026 to USD 2.79 billion by 2031. The market is expected to register a compound annual growth rate of 5.78% during the 2026-2031 forecast period. Rising demand for effective postpartum hemorrhage treatment, broader use of uterotonic medicines in gynecological procedures, and improving access to maternal healthcare are supporting market expansion.

Postpartum Hemorrhage Treatment Drives Market Growth

Postpartum hemorrhage remains a leading cause of maternal mortality worldwide, reinforcing the need for hospitals and maternity centers to maintain reliable access to carboprost tromethamine. The medicine is widely incorporated into obstetric emergency protocols, particularly when first-line treatments such as oxytocin or misoprostol do not adequately control bleeding caused by uterine atony.

Clinical evidence indicates that carboprost can control bleeding in a substantial proportion of refractory uterine atony cases after one or two doses. International efforts to improve postpartum hemorrhage reporting, standardize clinical protocols, and strengthen maternal safety practices are expected to support continued demand. Ongoing clinical research may also evaluate a broader role for carboprost in treatment pathways, potentially increasing its use in obstetric emergencies.

Postpartum hemorrhage treatment accounted for 61.62% of the carboprost tromethamine market in 2025, reflecting the product's established role in hospital maternity care. Regular obstetric emergency training and the adoption of standardized treatment guidelines are helping sustain consumption across developed and emerging healthcare systems.

Use in Surgical Gynecology Creates New Opportunities

Carboprost tromethamine is increasingly used during selected gynecological and obstetric procedures, including laparoscopic myomectomy and cesarean delivery, to help reduce blood loss and support efficient surgical management. This expanding clinical application is creating revenue opportunities beyond conventional postpartum hemorrhage treatment.

Evidence-based labor management guidelines and simulation-based training programs are also improving healthcare professionals' familiarity with uterotonic medicines. The expansion of obstetric emergency training in lower-resource settings may further increase appropriate carboprost use, particularly in regions working to reduce preventable maternal deaths.

Pregnancy abortion represents a smaller application segment but is forecast to expand at a CAGR of 9.21% through 2031. Growth is being supported by improving access to reproductive healthcare in selected emerging markets. However, differences in national regulations and political conditions are expected to produce uneven adoption across North America, Europe, and other regions.

Generic Availability Improves Market Accessibility

New generic product launches are helping improve the affordability and availability of carboprost tromethamine. Greater price accessibility may support adoption among hospitals, public health systems, and maternity facilities operating under constrained budgets. At the same time, investments in pharmaceutical manufacturing and active pharmaceutical ingredient production are strengthening regional supply capabilities.

Market growth may be moderated by carboprost's gastrointestinal and cardiopulmonary side-effect profile. Frequently reported reactions include vomiting, diarrhea, and temporary fever, while bronchospasm may occur in patients with asthma. These safety considerations can lead clinicians to select alternative uterotonic agents for certain patients. Reports involving incorrect administration also highlight the importance of clear protocols, appropriate storage, and ongoing clinical training.

Cold-chain requirements present another challenge, especially in low- and middle-income countries where rural healthcare facilities may lack dependable temperature-controlled logistics. Continued supply-chain modernization will be important for expanding access while maintaining product quality and availability.

North America Leads While Asia-Pacific Records Fastest Growth

North America held 40.75% of the global carboprost tromethamine market in 2025. The region benefits from established clinical guidelines, broad insurance coverage, advanced hospital infrastructure, and dependable cold-chain logistics. Regulatory oversight also supports consistent product quality, although recent product withdrawals may concentrate manufacturing among fewer well-capitalized suppliers.

Asia-Pacific is projected to record the fastest regional CAGR of 7.62% through 2031. Public healthcare initiatives, expanding maternity coverage, growth in local pharmaceutical manufacturing, and rapid digital health adoption are improving treatment access. India's pharmaceutical manufacturing incentives are also supporting domestic production capabilities. Nevertheless, cold-chain limitations in rural areas may continue to restrict market penetration.

Europe is expected to post steady growth, supported by universal healthcare funding and standardized obstetric protocols. Regional differences in reproductive health regulations and increased use of alternative bleeding-control therapies may affect demand. The Middle East and Africa and South America are also anticipated to experience improving adoption as maternal health programs, pharmaceutical distribution networks, and temperature-controlled supply chains continue to develop.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Prevalence Of Postpartum Haemorrhage (PPH)

4.2.2 Expanding Use Of Uterotonics In Surgical Gynaecology

4.2.3 Generic Launches Driving Price Accessibility

4.2.4 Increasing Obstetric Emergency Training In Low-Resource Settings

4.2.5 AI-Guided Early-Warning Systems For Maternal Bleeding

4.2.6 Integration Of Carboprost In Obstetric Tele-Health Bundles

4.3 Market Restraints

4.3.1 Gastro-Intestinal & Cardio-Pulmonary Side-Effect Profile

4.3.2 Stringent Cold-Chain Requirements In LMICs

4.3.3 Growing Preference For Tranexamic Acid As First-Line Therapy

4.3.4 Legal Restrictions On Medical Abortion In Key Regions

4.4 Value / Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technology Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Bargaining Power of Suppliers

4.7.2 Bargaining Power of Buyers

4.7.3 Threat of New Entrants

4.7.4 Threat of Substitutes

4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

5.1 By Application

5.1.1 Postpartum Haemorrhage Treatment

5.1.2 Pregnancy Abortion (2nd Trimester)

5.2 By Distribution Channel

5.2.1 Hospital Pharmacies

5.2.2 Retail Pharmacies

5.2.3 Online Pharmacies

5.3 By Dosage Form

5.3.1 250 g/mL Injectable Solution

5.3.2 Lyophilised Powder for Reconstitution

5.4 By Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)

6.3.1 Pfizer Inc.

6.3.2 Dr. Reddy's Laboratories Ltd

6.3.3 Fresenius Kabi

6.3.4 Teva Pharmaceutical Industries

6.3.5 Amneal Pharmaceuticals LLC

6.3.6 Caplin Steriles Limited

6.3.7 ANGUS Chemical Company

6.3.8 Aurobindo Pharma

6.3.9 Evacure Biotech

6.3.10 Intas Pharmaceuticals

6.3.11 Zydus Lifesciences

6.3.12 Sun Pharma

6.3.13 Lupin Ltd

6.3.14 Cipla Ltd

6.3.15 Hikma Pharmaceuticals

6.3.16 Gland Pharma

6.3.17 Jiangsu Hengrui Pharma

6.3.18 Ferring Pharmaceuticals

6.3.19 Steriscience Specialities

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/bt15kd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.